FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Reiterates Buy Opinion On Shares Of Signet Jewelers Limited

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our 12-month target at $100, applying a forward P/E of 9.3x our FY 27 (Jan) earnings estimate compared to the three-year historical average at 11.6x and five-year average at 10.9x. The industry mean peer average is 11.7x. Following a strong earnings beat of +13% vs. the consensus in Q1 FY 27, we raise our FY 27 EPS estimate to $10.80 (prior $10.51) and increase FY 28's to $12.50 ($11.25). Our revenue projections are $6.84B in FY 27 and $7.0B in FY 28. SIG's physical stores delivered 3.8% same-store sales growth in Q1 FY 27, sharply outperforming the 4.9% decline in e-commerce and demonstrating that well-located, experiential jewelry stores are delivering. The $100M cost saving program provides margin expansion runway with 150 bps of operating margin expansion potential, a buffer to higher input costs and promotional intensity. SG&A expenses declined to 32.8% of total sales in Q1 FY 27 from 34.1% a year ago. We are monitoring digital strategy challenges in e-commerce that need improvement.

Related Articles

Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Dexcom Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $83 (from $67), 32x our 2026 EPS estimate, near DXCM's one-year historical forward average of 32.9x and well below its longer-term historical averages to reflect increased competition within the continuous glucose monitoring space, in our view. We lift our 2026 EPS estimate by $0.01 to $2.59 and raise our 2027 estimate by $0.02 to $3.07. We think the addressable market for DXCM is large and far from saturated, but a slower sales growth rate is a concern, which we attribute to market share losses and slow progress in gaining additional insurance coverage. We see the upcoming CONNECT study (for type-2 non-insulin patients) readout as a potentially significant near-term catalyst which may drive enhanced insurance coverage. DXCM sees CMS coverage for all individuals with diabetes by mid-2027, which it believes will increase its addressable U.S. market for type-2 non-insulin intensive diabetes by around 80% to 27M people.

$DXCM
Research

Research Alert: CFRA Reiterates Sell Rating On Science Applications International Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our target by $20 to $100 on a P/E of 9.2x our FY 28 (Jan.) EPS view, below historical (13.6x) and peers (12.6x), reflecting lower revenue expectations. We raise our FY 27 EPS estimate to $10.13 from $9.50 and FY 28's to $10.90 from $10.65. Management raised FY 27 guidance across key profitability metrics while maintaining revenue expectations, reflecting confidence in margin sustainability but continued caution on top-line growth. Adj. EBITDA guidance increased to $720M-$730M from $705M-$715M, with margin guidance raised to 10.1%-10.3% from 9.9%-10.1%. Adj. diluted EPS guidance was lifted to $9.90-$10.10 from $9.50-$9.70. However, revenue guidance remained unchanged, implying organic declines of 2%-4% for FY 27, suggesting a cautious outlook on the procurement environment despite the quarter's stabilization.Before becoming more constructive, we need to see sustained strong bookings drive top-line growth, proving SAIC can execute its portfolio pivot and offset significant recompete headwinds.

$SAIC
Research

Research Alert: Hpe Q2: Massive Beats And Guidance Increases As Ai Tailwinds Strengthen

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:HPE reported Q2 FY 26 (Apr-Q) results that blew away consensus expectations, with non-GAAP EPS of $0.79 (+108% Y/Y) beating expectations for $0.53 and revenue of $10.68B (+40% Y/Y) coming in ahead of the Street's $9.76B view. Non-GAAP gross margin expanded 750 bps Y/Y while operating margin of 13.3% was up 530 bps. Results reflect growing AI demand and the strength of HPE's networking portfolio, with Networking sales surging 148% Y/Y (driven by the Juniper acquisition) and Cloud & AI segment revenue growing 23% Y/Y to $7.7B. FY 26 guidance was raised materially, with HPE's revenue midpoint now at $44.9B (consensus $40.84B), non-GAAP EPS lifted to a midpoint of $3.40 from a prior $2.40 view (consensus $2.42), and FCF guidance upped to at least $3.5B from at least $2.0B. Management also provided initial FY 27 sales growth expectations at about 10%, placing FY 27 sales around $49.4B (14% above consensus) in a confident move that reflects improving visibility and strengthening AI tailwinds.

$HPE